Drug Approval | April 17, 2025
Lupin receives EIR from USFDA for its injectable facility in Nagpur
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
the inspection conducted from January 27 to January 31, 2025
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
The inspection was carried out from January 28 to February 1, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
The trademark rights for these brands will be transferred to Lupin by March next year.
Reaffirms Lupin’s commitment to sustainable resource management
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Subscribe To Our Newsletter & Stay Updated
